LIBTAYO can help your
immune system fight
advanced CSCC

What is LIBTAYO?

LIBTAYO is the first and only medicine approved by the Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation.

What is immunotherapy?

Immunotherapy can help the body’s immune system fight cancer. LIBTAYO is a type of immunotherapy treatment called a programmed death receptor-1 (PD-1) inhibitor. LIBTAYO is not chemotherapy or radiation therapy.

Is LIBTAYO right for me?

LIBTAYO may be right for people with CSCC that:

has spread (metastasized)


cannot be
cured by surgery or radiation

In 2 ongoing clinical trials:

  • 47.2% of patients (51 of 108) saw an improvement in their condition with LIBTAYO (objective response rate)
  • 61% of patients (31 of 51) who responded to LIBTAYO had responses that lasted 6 months or longer
  • Responses lasted between 1 month and 15.2+ months (still ongoing at time of last follow-up)
Ask your healthcare provider whether LIBTAYO is a treatment option you should consider.